xanderla implantaat süstlis
teva b.v. - gosereliin - implantaat süstlis - 3,6mg 2tk; 3,6mg 3tk
xanderla implantaat süstlis
teva b.v. - gosereliin - implantaat süstlis - 10,8mg 3tk; 10,8mg 2tk
reseligo implantaat süstlis
zentiva k.s. - gosereliin - implantaat süstlis - 10,8mg 1tk; 10,8mg 3tk
reseligo implantaat süstlis
zentiva k.s. - gosereliin - implantaat süstlis - 3,6mg 3tk
firmagon
ferring pharmaceuticals a/s - degareliks - eesnäärmevähk - endokriinset ravi - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
porceptal süstelahus
intervet international b.v. - busereliin - süstelahus - 4mcg 1ml 10ml 5tk; 4mcg 1ml 50ml 1tk; 4mcg 1ml 5ml 10tk; 4mcg 1ml 5ml 1tk; 4mcg 1ml 2.5ml 10tk
geslin süstelahus
mevet s.a.u. - busereliin - süstelahus - 0,004mg 1ml 20ml 1tk; 0,004mg 1ml 20ml 5tk
ovulike süstelahus
t. p. whelehan son & co. limited - busereliin - süstelahus - 4mcg 1ml 10ml 5tk; 4mcg 1ml 10ml 500tk; 4mcg 1ml 10ml 50tk; 4mcg 1ml 10ml 250tk; 4mcg 1ml 10ml 100tk
ringer acetate fresenius infusioonilahus
fresenius kabi polska sp. z o.o. - elektrolüüdid - infusioonilahus - 1000ml 1tk